Investors may have parted too soon and too fast from a handful of stocks, indicating they may be due for a rebound ahead. Stocks were lower again on Thursday , following a sharp pullback one day earlier and ahead of a long three-day weekend and market holiday. U.S. equities have been whipsawed in April following President Donald Trump's rollout of so-called reciprocal tariffs . The president temporarily walked back a large portion of the import duties last week, and further exempted smartphones, computers and chips on Sunday. But a blanket 10% tariff on most countries remains in place, as well as a tariff of more than 100% on goods brought in from China. The back-and-forth trade policy has kept global trading partners and investors on edge, trying to guess the president's next move. The tariffs have been a particular pain point for investors, with the S & P 500 now down nearly 10% in 2025. But this year's selling and rush to safety may be overdone, at least in spots. CNBC Pro screened LSEG data to identify the most oversold stocks on Wall Street, measuring their 14-day relative strength index, or RSI. An RSI reading below 30 indicates a stock may be oversold and could be poised to rebound. Conversely, a 14-day RSI above 70 can indicate a stock may be overbought and due to weaken. Global Payments made the list. Shares have slumped nearly 38% in 2025 and are off 18% this week alone. But the financial technology stock's 14-day RSI of 27.5 signals shares could be due for an uptick after a strong bout of selling. Analysts polled by LSEG have a consensus buy rating on the stock, and the average price target implies more than 72% upside over the coming 12 months. GPN YTD mountain Global Payments stock in 2025. The company on Thursday announced plans to acquire Worldpay for $22.7 billion, while selling its Issuer Solutions business. AbbVie turned up on the screen after the pharmaceutical stock tumbled 19% over the past month. Health care regained some ground last week after Trump said he would pause some tariffs, including those on imported drugs, by 90 days. The Illinois-based stock has a 14-day RSI of 28.6, while analysts surveyed by LSEG maintain a consensus buy rating. The average price targets call for about 24% upside moving forward. ABBV YTD mountain AbbVie stock in 2025. Get Your Ticket to Pro LIVE Join us at the New York Stock Exchange!| Uncertain markets? Gain an edge with CNBC Pro LIVE , an exclusive, inaugural event at the historic New York Stock Exchange. In today's dynamic financial landscape, access to expert insights is paramount. As a CNBC Pro subscriber, we invite you to join us for our first exclusive, in-person CNBC Pro LIVE event at the iconic NYSE on Thursday, June 12. Join interactive Pro clinics led by our Pros Carter Worth, Dan Niles and Dan Ives, with a special edition of Pro Talks with Tom Lee. You'll also get the opportunity to network with CNBC experts, talent and other Pro subscribers during an exciting cocktail hour on the legendary trading floor. Tickets are limited!
